Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 15/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 15/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 15/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 15/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 15/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 15/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073421 | 0.87 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5069747 | 0.87 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5070781 | 0.85 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6053222 | 0.85 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5073379 | 0.83 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5069735 | 0.82 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5069732 | 0.82 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5073363 | 0.81 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5070780 | 0.81 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5071697 | 0.81 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | PSEN1 4/4885PSEN2 3/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.